AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00180388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic vein harvesting
Study NCT00180388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open vein harvesting
Study NCT02273661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (Ambisome®)
Description: An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
Study NCT02273661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An aerosol of isotonic saline x 1/ week will be administered during 6 months
Study NCT02497183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: A repeat ultrasound exam following oral contrast material consumption
Study NCT02497183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iodine based solution of oral contrast material
Description: A solution of oral contrast material that is routinely used in our institution prior to performing a computed tomographic (CT) examinations of the gastrointestinal tract will be given prior to performing the repeat ultrasound/
Study NCT01774799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care planning intervention
Study NCT01774799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Study NCT03725384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate 300Mg Tablet
Description: oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
Study NCT03725384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate 300Mg Tablet
Description: oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
Study NCT03725384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C 500Mg tablet
Description: Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
Study NCT03725384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 500Mg tablet
Description: Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
Study NCT02369913 — intervention group
Intervention type: OTHER
Intervention: Blood Drawn
Description: Both groups will have 1 teaspoon of blood drawn for analysis.
Study NCT02733445 — intervention group
Intervention type: DRUG
Intervention: dasatinib
Study NCT02733445 — intervention group
Intervention type: DRUG
Intervention: nilotinib
Study NCT01553019 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Description: Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
Study NCT01553019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
Study NCT04531241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS 1-DAY
Description: senofilcon A contact lenses made with a novel manufacturing technology
Study NCT04531241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS 1-DAY
Description: senofilcon A contact lenses made with the current manufacturing technology
Study NCT01603589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation
Description: We use a prototype AHEPA (modular type IV) circuit comprised of the standard and a standby accessory. Components of the standard circuit include: aortic cannula, three-stage venous cannula, coated tubing, a centrifugal pump, a new-generation membrane oxygenator with integrated arterial filter, a venous air removal device, a soft coated bag and pulmonary artery as well as aortic root vent. In addition, there is a standby hard-shell reservoir in parallel to the venous line, so as to convert the closed system to an open one. The standby component is bridged to the main circuit with an afferent line which is connected just before the VARD sending blood to the hard-shell reservoir and an efferent that re-directs it back to the VARD. A cell-saver device is added to the circuit for collecting shed blood and washing red blood cells for autotransfusion.
Study NCT01603589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting under conventional extracorporeal circulation
Description: A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
Study NCT00556894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: orally q12h
Study NCT00556894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally q12h
Study NCT04525612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-BNU-PSMA
Description: Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.
Study NCT02048020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT02048020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT02048020 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study NCT02048020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00849966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex suspension
Description: Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO.
Study NCT00849966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celebrex suspension
Description: Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO.
Study NCT00849966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO.
Study NCT03166280 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir 400 mg
Description: treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day
Study NCT03166280 — intervention group
Intervention type: DRUG
Intervention: Daclatasvir 60 mg/day
Description: treatment for hepatitis c by Daclatasvir 60 mg/day
Study NCT01899599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PankoMab-GEX
Description: start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01899599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02371707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg formulation A (test)
Description: Tablet for oral use, single dose
Study NCT02371707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg formulation B (reference)
Description: Tablet for oral use, single dose
Study NCT01567969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive In-home Child and Adolescent Psychiatric Service
Description: A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
Study NCT00690534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Regular
Description: insulin, 0.2 mU/kg/min for 3 hours
Study NCT01567969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Child Treatment Coordination
Description: A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
Study NCT03812965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 2 units/point of botulinum toxin type A
Study NCT02927457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1%
Description: A cream for topical application with a concentration of 1% GSK2646264.
Study NCT02927457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching Placebo topically.
Study NCT03789201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS EEG
Description: attempt to use TMS EEG to measure connectivity between cortical areas
Study NCT03789201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS fMRI
Description: compare measurements to established functional connectivity measures; e.g., EEG coherence and fMRI
Study NCT03076424 — intervention group
Intervention type: OTHER
Intervention: no intervention used
Description: Patients will be giving a blood sample after 8 hours of fasting.
Study NCT02854865 — intervention group
Intervention type: OTHER
Intervention: echocardiography
Description: assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
Study NCT01722058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peptide application
Study NCT01782651 — intervention group
Intervention type: DRUG
Intervention: Lapatinib plus capecitabine
Description: Lapatinib plus capecitabine
Study NCT02567071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perineal impregnated swab
Description: After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
Study NCT02567071 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: clean swab
Description: After planned C-section birth, newborns will suck on clean swab.
Study NCT00020670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD 40
Study NCT01942629 — intervention group
Intervention type: OTHER
Intervention: their will be no intervention in any of the groups, the study is retrospective
Study NCT01465464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orantinib (TSU-68)
Description: 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
Study NCT01465464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet was administered orally twice per day after meals, morning and evening.
Study NCT04603729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 2 MG/ML
Description: Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants
Study NCT04603729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Injection
Description: methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
Study NCT02388984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound danshen dripping pills
Description: Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
Study NCT02388984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
Study NCT04383925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG-Japan
Description: Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).
Study NCT04383925 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Russia
Description: Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)
Study NCT01467518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
Study NCT01467518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methadone
Description: Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
Study NCT02008487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wound powder application
Description: Powder application to wound per protocol.
Study NCT04150107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 Treatment A
Description: Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime
Study NCT04150107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 Treatment B
Description: Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
Study NCT04150107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Fish oil capsule
Study NCT04417361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab Prefilled Syringe
Description: Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
Study NCT01967810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG1005
Description: ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks
Study NCT01967810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
Study NCT03091478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg every 3 weeks
Study NCT04417361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
Study NCT04661046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Description: Chinese medicine prescription
Study NCT03593057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy protocol and self-care advice and body awareness.
Study NCT03593057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Advice on self-care and body awareness.
Study NCT04385186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactivated convalescent plasma
Description: Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol~Day 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma
Study NCT04385186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Support treatment
Description: Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
Study NCT04385186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Support treatment
Description: Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
Study NCT02341352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoride varnish
Description: Sodium fluoride 50mg/ml
Study NCT02341352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Yolk
Description: anti-Streptococcus mutans IgY
Study NCT02341352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
Study NCT01867762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 49095397
Description: JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
Study NCT01867762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
Study NCT01862536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Daily use of study drug to treat pulmonary hypertension.
Study NCT01862536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Daily use in double blind study.
Study NCT02825979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon-based PVI
Description: Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
Study NCT03370718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT02825979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Arrhythmic Drug Therapy
Description: Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
Study NCT00718146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split virion, inactivated Influenza vaccine
Description: 0.5 mL, Intramuscular (IM)
Study NCT03370718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT03370718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT02290015 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
Study NCT01114126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu-P11
Description: comparison of different dosages of drug
Study NCT02290015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).